Advanced Breast Cancer Clinical Trial
Official title:
A Phase I Study of LX-039 Tablets in Postmenopausal Patients With ER+, HER2- Advanced Breast Cancer After Failure of Endocrine Therapy
Verified date | October 2020 |
Source | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I dose escalation and expansion study in patients with ER+, HER2- advanced breast cancer to explore the tolerance, PK/PD(pharmacokinetics/pharmacodynamics) profiles and preliminary anti-tumor activity of different doses of LX-039 tablets. The trial consists of two parts, dose escalation and dose expansion. Part 1 is the dose escalation phase with initial 6 dose groups, and "3 + 3" design is used to explore MTD of the drug; Part 2 is the dose expansion phase with 2 ~ 3 doses selected for expansion according to the escalation results of Part 1, and more subjects are enrolled to further observe the tolerance and preliminary anti-tumor activity of the drug. After the completion of dose expansion, the recommended phase II dose (RP2D) will be determined after discussion based on the obtained tolerance and PK/PD data.
Status | Completed |
Enrollment | 44 |
Est. completion date | February 7, 2023 |
Est. primary completion date | August 8, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Be able to read and sign the informed consent form. 2. Adult females (aged =18 and =75 years). 3. Be diagnosed with breast cancer confirmed by pathological examination. 4. Be histologically or cytologically confirmed estrogen receptor positive (ER+=1% positive staining). 5. Be postmenopausal. 6. Subjects who have previously received endocrine therapy and obtained benefit. 7. ECOG(Eastern Cooperative Oncology Group) score = 1. 8. Subjects in part2 of the study need to have measurable lesions that meet RECIST 1.1 criteria. 9. Has recovered from toxicity or injury from prior chemotherapy/radiotherapy . 10. Enough hematology and organ function. 11. Expected survival>3 months. Exclusion Criteria: 1. Subjects with HER2-overexpressing breast cancer. 2. Subjects with known brain metastases or other central nervous system metastases that are symptomatic or untreated. 3. Patients with symptomatic advanced disease who have spread to the viscera and are at risk of life-threatening complications. 4. Subjects who received second-line or above chemotherapy. 5. Subjects with known allergy to this product or any of its components. 6. Subjects who previously used other estrogen receptor down regulators than fulvestrant. 7. Subjects who received endocrine therapy or other anti-tumor agent or radiotherapy within 4 weeks prior to study entry. 8. Subjects who received cell therapy or tumor vaccine therapy; 9. Subjects with severe immunosuppression . 10. Severe or uncontrolled disease. 11. Subjects with diseases or abnormalities that may affect the administration and absorption of drugs. 12. Subjects with other malignancy within 5 years prior to study entry. 13. Subjects with other high risks of thrombosis or require long-term use of antiplatelet drugs. 14. Subjects with history of definite neurological or psychiatric disorders in the past. 15. Subjects who are HIV(human immunodeficiency virus) antibody positive, HBsAg(hepatitis B surface antigen) positive or HCV(hepatitis C virus)antibody positive. 16. Subjects with other uncontrolled malignant/non-malignant diseases, significant laboratory abnormalities, participation in the study may increase the risk. |
Country | Name | City | State |
---|---|---|---|
China | Fudan University Shanghai Cancer Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To explore the tolerance of LX-039 in ER +, HER2 - patients with advanced breast cancer | Incidence of dose limiting toxicities (DLTs) | DLT observation period(5 weeks for dose escalation, 4 weeks for dose expansion) | |
Secondary | The safety of LX-039 in ER +, HER2 - patients with advanced breast cancer | Number of participants with treatment related. adverse events as assessed by CTCAE v5.0 | through study completion,an average of 1 year | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | Objective response rate (ORR) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | proportion of subjects with complete response (CR) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | proportion of subjects with partial response (PR) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | proportion of subjects with stable disease (SD) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | proportion of subjects with progressive disease (PD) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | duration of response (DoR) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | disease control rate (DCR) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | clinical benefit rate (CBR) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | time to progression (TTP) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | progression-free survival (PFS) | through study completion,an average of 1 year. | |
Secondary | To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1. | overall survival (OS) | through study completion,an average of 1 year. | |
Secondary | Comparison of changes in maximum uptake ability of FES(progression free survival) in breast cancer lesions before and after treatment with LX-039 by PET(positron emission tomography) scan (performed in some subjects) | Decrease in SUVmax in comparison with that before treatment | Up to the third day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after a single dose of LX-039 | Peak Concentration (Cmax) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Peak Time (Tmax) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Elimination Half-life (t1/2) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Eliminate Rate Constant (Kel) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Mean Residence Time (MRT) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Area under plasma Concentration-time curve from 0 time to 24 hours (AUC0-24h) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Area under plasma Concentration-time curve from 0 time to sampling time t of the last measurable concentration (AUC0-last) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Area under plasma Concentration-time curve from administration (0) to infinity (AUC0-inf) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Apparent Total Clearance (CL/F) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after a single dose of LX-039 | Apparent Volume of Distribution (Vd/F) | Up to the third day of Cycle 0(Cycle 0 is 7 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Trough Concentration at Steady State (Css, min) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Peak Concentration at Steady State (Css, max) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Average Concentration at Steady State (Css, av) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Peak Time (Tss, max) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Apparent Volume of Distribution at steady state (Vss/F) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Steady-state Clearance Half-life (tss,1/2) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Total Body Clearance (CLss/F) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Coefficient of Fluctuation (DF) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Area under Plasma Concentration-time Curve at Steady State (AUCss) | Up to the Second day of Cycle 2(each cycle is 28 days) | |
Secondary | PK profiles after continuous administration of LX-039 | Accumulation Coefficient (Rac) | Up to the Second day of Cycle 2(each cycle is 28 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04653740 -
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
|
N/A | |
Completed |
NCT02091960 -
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05156619 -
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
|
||
Recruiting |
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
||
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Completed |
NCT00754325 -
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
|
Phase 2 | |
Recruiting |
NCT04953377 -
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
N/A | |
Completed |
NCT03240224 -
Bioinformation Therapy for Breast Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06193525 -
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
|
Phase 2 | |
Completed |
NCT03312738 -
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
|
Phase 2 | |
Active, not recruiting |
NCT05063786 -
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
|
Phase 3 | |
Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02499146 -
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Completed |
NCT04408118 -
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03205761 -
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04316169 -
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT00546104 -
Phase II Dasatinib Study in Advanced Breast Cancer
|
Phase 2 |